Literature DB >> 31413790

Treatment of Cancer and Alzheimer's Disease by PROTAC Degradation of EGFR.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2019        PMID： 31413790      PMCID： PMC6691564          DOI： 10.1021/acsmedchemlett.9b00283

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  4 in total

Review 1.  Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.

Authors:  Debasis Das; Jian Hong
Journal:  Eur J Med Chem       Date:  2019-03-07       Impact factor: 6.514

Review 2.  PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.

Authors:  Mariell Pettersson; Craig M Crews
Journal:  Drug Discov Today Technol       Date:  2019-02-13

Review 3.  EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer.

Authors:  Eugene Tulchinsky; Oleg Demidov; Marina Kriajevska; Nickolai A Barlev; Evgeny Imyanitov
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-11-10       Impact factor: 10.680

Review 4.  The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance.

Authors:  Meng-Shih Weng; Jer-Hwa Chang; Wen-Yueh Hung; Yi-Chieh Yang; Ming-Hsien Chien
Journal:  J Exp Clin Cancer Res       Date:  2018-03-16
  4 in total
  3 in total

1.  Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality.

Authors:  Philip P Chamberlain; Laura A D'Agostino; J Michael Ellis; Joshua D Hansen; Mary E Matyskiela; Joseph J McDonald; Jennifer R Riggs; Lawrence G Hamann
Journal:  ACS Med Chem Lett       Date:  2019-11-12       Impact factor: 4.345

2.  PROTACs technology for treatment of Alzheimer's disease: Advances and perspectives.

Authors:  Hiroyuki Inuzuka; Jing Liu; Wenyi Wei; Abdol-Hossein Rezaeian
Journal:  Acta Mater Med       Date:  2022-01-21

Review 3.  Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets.

Authors:  Yungang Wang; Shouyan Deng; Jie Xu
Journal:  Cancer Biol Med       Date:  2020-08-15       Impact factor: 4.248
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.